Featured Research

from universities, journals, and other organizations

Medication May Slow Progression Of Alzheimer Disease

Date:
June 18, 2003
Source:
Indiana University
Summary:
A medication used to treat the symptoms of mild-to-moderate Alzheimer disease may actually do more - it may be able to delay progression of the disorder, according to a study conducted at the Indiana University School of Medicine.

A medication used to treat the symptoms of mild-to-moderate Alzheimer disease may actually do more - it may be able to delay progression of the disorder, according to a study conducted at the Indiana University School of Medicine.

Related Articles


The study, which appears in the June issue of Archives of Neurology, enabled researchers to evaluate a change in cognition observed in patients who prematurely discontinued treatment with placebo or Exelon (rivastigmine tartrate), a medication prescribed for many patients.

"If Exelon only had an effect on the symptoms of the disease, we would have expected rapid deterioration in patients' cognition to the level observed in the placebo group after treatment withdrawal, but that was not the case with this study," notes Martin Farlow, M.D., professor of medicine at the IU School of Medicine and director of the Alzheimer Clinic at Indiana University Hospital.

So what did Dr. Farlow, principal investigator and lead author of the study, and his colleagues discover?

"We found that patients who received Exelon before withdrawing from the study showed significantly less cognitive decline than placebo-treated patients, suggesting a possible effect in delaying the biological progression of Alzheimer's."

At 26 weeks after discontinuing treatment, the patients who initially had used the medication showed less cognitive decline than patients who had stopped taking the dummy medication.

Exelon is a cholinesterase inhibitor, a laboratory-produced agent designed to enhance memory and other cognitive functions by influencing certain chemical activities in the brain. One particular chemical - acetylcholine - is released by one brain cell to transmit a message to another cell. Once a message is received, enzymes are broken down for reuse.

In the Alzheimer-afflicted brain, the cells using acetylcholine are damaged or destroyed, resulting in lower levels of the chemical messenger.

"Cholinesterase inhibition is the most extensively researched and best therapeutic approach for the symptomatic treatment of Alzheimer disease, providing clinical benefits presumably through an increase of acetylcholine levels and enhancing neurotransmission," Dr. Farlow said.

Alzheimer disease is a neurodegenerative disorder - and the most common form of dementia - mainly characterized by the progressive and irreversible loss of nerve cells located in specific brain areas. It attacks the brain and results in impaired memory, thinking and behavior. There is no known cure for this disease, which affects four million in the United States and more than 10 million worldwide.

Other investigators participating in the study were Steven Potkin, M.D., of the Brain Imaging Center at the University of California-Irvine; and Dario Mirski, M.D., Barbara Koumaras and Jeffrey Veach, Novartis researchers in East Hanover, N.J.

Exelon, manufactured by Novartis Pharmaceuticals Corp., was approved for consumer use by the Food and Drug Administration in 2000.


Story Source:

The above story is based on materials provided by Indiana University. Note: Materials may be edited for content and length.


Cite This Page:

Indiana University. "Medication May Slow Progression Of Alzheimer Disease." ScienceDaily. ScienceDaily, 18 June 2003. <www.sciencedaily.com/releases/2003/06/030618075716.htm>.
Indiana University. (2003, June 18). Medication May Slow Progression Of Alzheimer Disease. ScienceDaily. Retrieved February 1, 2015 from www.sciencedaily.com/releases/2003/06/030618075716.htm
Indiana University. "Medication May Slow Progression Of Alzheimer Disease." ScienceDaily. www.sciencedaily.com/releases/2003/06/030618075716.htm (accessed February 1, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, February 1, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC: Get Vaccinated for Measles

CDC: Get Vaccinated for Measles

Reuters - US Online Video (Jan. 30, 2015) The CDC is urging people to get vaccinated for measles amid an outbreak that began at Disneyland and has now infected more than 90 people. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Obama To Outline New Plan For Personalized Medicine

Obama To Outline New Plan For Personalized Medicine

Newsy (Jan. 30, 2015) President Obama is expected to speak with drugmakers Friday about his Precision Medicine Initiative first introduced last week. Video provided by Newsy
Powered by NewsLook.com
NFL Concussions Down; Still on Parents' Minds

NFL Concussions Down; Still on Parents' Minds

AP (Jan. 30, 2015) The NFL announced this week that the number of game concussions dropped by a quarter over last season. Still, the dangers of the sport still weigh on players, and parents&apos; minds. (Jan. 30) Video provided by AP
Powered by NewsLook.com
U.S. Wants to Analyze DNA from 1 Million People

U.S. Wants to Analyze DNA from 1 Million People

Reuters - US Online Video (Jan. 30, 2015) The U.S. has proposed analyzing genetic information from more than 1 million American volunteers to learn how genetic variants affect health and disease. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins